TYRA Tyra Biosciences, Inc.

NASDAQ
$21.76

Tyra Biosciences, Inc. (TYRA) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is a loss of $0.66 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -25.0% since its last earnings release on August 4, 2026.

Tyra Biosciences Missed Consensus Estimates
Tuesday, August 4, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.66)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $24.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Tyra Biosciences, Inc.

Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.